TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29306203
Drug: Pulsed low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pulsed low-dose rate radiotherapy (PLDR) - 10 fractions of 2 Gy/day, with an interval of 3 minutes, for 5 days per week; dose rate 6.67 cGy/min
Study: 29306203
Drug: Pulsed low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pulsed low-dose rate radiotherapy (PLDR)
Study: 29306459
Drug: Serum uric
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum uric acid (sUA) levels (using diuretics)
Study: 29306459
Drug: Serum uric
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum uric acid (sUA) levels (not using diuretics)
Study: 29306506
Drug: On-time dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-time dosing (control group)
Study: 29306506
Drug: Substantially late
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substantially late dose 3 (group 2)
Study: 29306506
Drug: Substantially late
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substantially late dose 2, on-time dose 3 (group 3)
Study: 29306506
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses substantially late (group 4)
Study: 29306506
Drug: On-time dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-time dose 2
Study: 29306506
Drug: Substantially late
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substantially late dose 2
Study: 29306769
Drug: Ipilimumab at
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab at a dose of 10 mg/kg in week 1, 4, 7, 10 followed by 3-month maintenance treatment for a maximum of 48 weeks
Study: 29309319
Drug: Low-risk group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-risk group (50 mg/kg TXA bolus)
Study: 29309319
Drug: High-risk group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk group (loading dose 30 mg/kg, infusion 16 mg/kg/h with 2 mg/kg in pump prime)
Study: 29310641
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment (specifics not provided)
Study: 29310641
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of life questionnaires (EuroQoL EQ-5D-5 L, EORTC QLQ-C30, QLQ-BR23, Hospital Anxiety and Depression Scale)
Study: 29310710
Drug: Active LLLT
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active LLLT (low-level laser therapy)
Study: 29310869
Drug: Intravenous vascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vascular access
Study: 29311069
Drug: Meropenem-Vaborbactam, single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem-Vaborbactam, single-dose administration, specific dosage not mentioned.
Study: 29311086
Drug: Artemether-Lumefantrine; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-Lumefantrine; specific dosage and duration not provided
Study: 29311094
Drug: Telavancin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin at fixed doses
Study: 29312948
Drug: Controlled diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled diet of 1.2 g/kg protein for 2 days
Study: 29313282
Drug: Ertugliflozin 5
Normalized name: ertugliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 5 mg once daily and Sitagliptin 100 mg once daily (E5/S100)
Study: 29313282
Drug: Ertugliflozin 15
Normalized name: ertugliflozin 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 15 mg once daily and Sitagliptin 100 mg once daily (E15/S100)
Study: 29315015
Drug: Forced expression
Normalized name: benzalkonium chloride Topical Solution [Clean Force]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced expression of a dominant-negative TGF-β receptor type 2 (DNRII)
Study: 29317417
Drug: New group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: New group-based treatment programme combining physical exercise and dietary therapy
Study: 29318759
Drug: Dietary sodium
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary sodium intake of 500 mg/d higher
Study: 29318795
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion rates at T1, T2, and T3
Study: 29319721
Drug: Vasopressin infusion
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin infusion at 0.04 U/min for one hour
Study: 29319721
Drug: Baseline noradrenaline
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline noradrenaline dose
Study: 29319721
Drug: Noradrenaline dose
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline dose higher than 0.38 mcg/kg/min
Study: 29319932
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate 200 mg (single oral dose)
Study: 29321026
Drug: Combination intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination intervention administered by trained lay health workers including appointment reminders via text and phone calls, follow-up and tracking for missed clinic visits, PMTCT health education at home visits and during clinic visits, and retention and adherence support and counseling.
Study: 29321026
Drug: Combination intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination intervention administered by trained lay health workers.
Study: 29321041
Drug: Prophylactic proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic proton pump inhibitor
Study: 29321063
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment with autologous adipose-derived stromal vascular fraction (ADSVF) and microfat; 14 ml of microfat and approximately 20 million viable ADSVF cells injected.
Study: 29321075
Drug: H1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 vaccine alone (group 1)
Study: 29321075
Drug: H1/IC31® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1/IC31® vaccine (groups 2, 3, and 4)
Study: 29321155
Drug: Plasminogen replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasminogen replacement therapy
Study: 29322091
Drug: Toca 511
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toca 511 and Toca FC (extended-release 5-FC)
Study: 29324745
Drug: Digital intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital intervention for ADHD, 28 days of at-home treatment
Study: 29325133
Drug: Metformin (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (daily for 24 months)
Study: 29325161
Drug: Japanese Encephalitis
Normalized name: Japanese Encephalitis IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) booster
Study: 29325173
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccine (PCV13) or pneumococcal polysaccharide vaccine (PPV23)
Study: 29325173
Drug: Pneumococcal polysaccharide
Normalized name: pneumococcal polysaccharides (23)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal polysaccharide vaccine (PPV23)
Study: 29325238
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not prescribed antidepressants)
Study: 29325521
Drug: Single-agent gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent gemcitabine (1000 mg/m²)
Study: 29325595
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of 10% dextrose 5 mL/kg followed by a dextrose infusion in addition to standard care
Study: 29326029
Drug: Trastuzumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (8 mg/kg loading dose followed by 6 mg/kg), Pertuzumab (840 mg loading dose followed by 420 mg), Palbociclib (125 mg once a day for 21 days), Fulvestrant (500 mg every 4 weeks)
Study: 29326917
Drug: Daily PrEP
Normalized name: Zinc Oxide 238 mg in 1 mL / Titanium Dioxide 41 mg in 1 mL TOPICAL LOTION [bareMinerals Prep Step Mineral Shield Broad Spectrum SPF 50 Daily Prep]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily PrEP (one pill taken every day)
Study: 29326917
Drug: Event-driven PrEP
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Event-driven PrEP (pills taken only around specific risk events)
Study: 29326917
Drug: Periodic PrEP
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodic PrEP (daily dosing during periods of increased risk)
Study: 29327075
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg orally twice a day, oxaliplatin 85 mg/m2
Study: 29327182
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ferrous fumarate in tablet form (195 mg of elemental iron)
Study: 29327182
Drug: 1390 mg
Normalized name: Mg
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1390 mg ferrous gluconate as a solution (160 mg of elemental iron)
Study: 29330782
Drug: Vilaprisan 5
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 5 mg single oral administration
Study: 29330782
Drug: Vilaprisan administered
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan administered with itraconazole
Study: 29331969
Drug: Antithrombotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic treatment initiated at diagnosis
Study: 29331969
Drug: Guideline-recommended therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended therapy
Study: 29333165
Drug: Intramyocardial injections
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injections of autologous VEGF-A
Study: 29334491
Drug: AZL-M/CTD 20/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL-M/CTD 20/12.5 mg once daily titrated to 40/25 mg if needed
Study: 29334491
Drug: AZL-M/CTD 40/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL-M/CTD 40/12.5 mg once daily titrated to 80/25 mg if needed
Study: 29334491
Drug: OLM/HCTZ 20/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLM/HCTZ 20/12.5 mg once daily titrated to 40/25 mg if needed
Study: 29334491
Drug: AZL-M/CTD lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL-M/CTD lower dose
Study: 29334491
Drug: AZL-M/CTD higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL-M/CTD higher dose
Study: 29335333
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (initially pursued)
Study: 29335333
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active treatment (discontinued after admission)
Study: 29335831
Drug: Extracorporeal membrane
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal membrane oxygenation treatment
Study: 29338080
Drug: Cisplatin, gemcitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin, gemcitabine, and veliparib (80 mg twice daily on days 1 to 12)
Study: 29338080
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and gemcitabine (600 mg/m2 and 25 mg/m2 respectively)
Study: 29339269
Drug: Intravenous busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m2)
Study: 29339394
Drug: Finafloxacin; administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finafloxacin; administered orally
Study: 29339403
Drug: Azacitidine combined
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine combined with chemotherapy
Study: 29339691
Drug: Cross-sectional survey
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-sectional survey of public perception and knowledge of cholesterol treatment
Study: 29341967
Drug: Inhaled Nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Nitric Oxide (NO) at an initial dose of 10 (10, 15) ppm for adults, 20 (18, 20) ppm for children, and 17 (11, 20) ppm for neonates, administered for a median duration of 3.9 (1.9, 6.1) days for adults, 3.8 (1.8, 6.8) days for children, and 3.1 (1.0, 5.7) days for neonates.
Study: 29342267
Drug: 0.50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg/kg of SLD-PQ
Study: 29342267
Drug: 0.40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.40 mg/kg of SLD-PQ
Study: 29344432
Drug: WT1 peptide
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WT1 peptide vaccine with Montanide as an adjuvant
Study: 29344726
Drug: Elbasvir 50
Normalized name: elbasvir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir 50 mg plus grazoprevir 100 mg once daily for 12 weeks
Study: 29345044
Drug: TAK-063 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-063 at 0.3 mg/kg
Study: 29346377
Drug: Community-wide mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide mass drug administration (MDA) delivered door-to-door, twice annually for three years.
Study: 29346388
Drug: 18 mg
Normalized name: niacin 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg ivermectin tablet
Study: 29346388
Drug: 36 mg
Normalized name: pyrantel 136 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 mg ivermectin tablet
Study: 29346388
Drug: Standard weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weight-based regimen (150–200 μg/kg)
Study: 29346478
Drug: Enasidenib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enasidenib (50 to 650 mg/d during dose-escalation; 100 mg/d during phase 1 expansion and phase 2)
Study: 29346519
Drug: Cetuximab 400
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 400 mg/m2 loading dose in week 1 followed by 250 mg/m2 weekly and cisplatin 30 mg/m2 concurrent with 6 weeks of intensity-modulated radiotherapy (60-66 Gy in 30 daily fractions)
Study: 29346834
Drug: Ravidasvir (RDV)
Normalized name: Ravidasvir
DrugBank: Ravidasvir (DB15652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ravidasvir (RDV) 200 mg once daily plus ritonavir-boosted danoprevir (DNVr) 100 mg/100 mg twice daily and oral ribavirin (RBV) 1000/1200 mg/day for 12 weeks
Study: 29346833
Drug: Ficlatuzumab in
Normalized name: Ficlatuzumab
DrugBank: Ficlatuzumab (DB11680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ficlatuzumab in combination with Gefitinib
Study: 29347915
Drug: Self-reported current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported current insulin use
Study: 29347987
Drug: Clinical and
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical and biological parameters at ICU discharge including N-terminal pro-B type natriuretic peptide, high-sensitive troponin I, bioactive-adrenomedullin, and soluble-ST2.
Study: 29347993
Drug: Avelumab 10
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg by 1-h intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal.
Study: 29348128
Drug: Pevonedistat (PEV)
Normalized name: econazole nitrate Topical Powder [Pevaryl]
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pevonedistat (PEV) 20 or 30 mg/m² combined with azacitidine (AZA)
Study: 29349065
Drug: Omega-3 acids
Normalized name: Fish oil containing omega-3 acids
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 acids supplementation (2 g/day)
Study: 29349545
Drug: Bare-metal stents
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bare-metal stents (BMS) with clopidogrel 75 mg for 4 weeks
Study: 29349545
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (DES) without HTPR with clopidogrel for 6 months
Study: 29349545
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (DES) with HTPR with clopidogrel for 6 months
Study: 29349598
Drug: lumretuzumab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: lumretuzumab (1000 mg in Cohort 1; 500 mg in Cohorts 2 and 3) plus pertuzumab (840 mg loading dose followed by 420 mg in Cohorts 1 and 2; 420 mg without loading dose in Cohort 3) plus paclitaxel (80 mg/m2) every 3 weeks
Study: 29350386
Drug: VKAs (acenocoumarol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VKAs (acenocoumarol, warfarin)
Study: 29350386
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of dabigatran and rivaroxaban
Study: 29350463
Drug: Vemurafenib 720
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 720 mg BID
Study: 29350463
Drug: Vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 960 mg BID
Study: 29351986
Drug: Ruxolitinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (oral JAK1/2 inhibitor), at least six cycles administered to 9 patients (27.3%), more than six cycles to 6 patients (18.2%)
Study: 29351986
Drug: Ruxolitinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (oral JAK1/2 inhibitor)
Study: 29352703
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin plus mini-hyper-CVD chemotherapy
Study: 29352719
Drug: Unfavorable-risk genetics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfavorable-risk genetics, age ≥ 75 years, race, and treatment choice at enrollment
Study: 29355412
Drug: Fluoride in
Normalized name: sulfur hexafluoride intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride in office (drops/tablets and/or varnish) applied by a health care professional by age 1 y
Study: 29355439
Drug: Minidose glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Minidose glucagon (150 μg, increased to 300 μg if needed)
Study: 29355904
Drug: Ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol mebutate gel, 0.015% for face/scalp and 0.05% for trunk/extremities, applied for treatment of AK
Study: 29357099
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for mean 21 weeks (sd 5, range 8-24)
Study: 29357826
Drug: Chair muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chair muscle strength training twice a week for 12 weeks
Study: 29357841
Drug: ZIKV RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZIKV RNA presence testing in various body fluids (blood, urine, semen, vaginal secretion/menstrual blood, rectal swab, oral fluids, tears, sweat, breast milk)
Study: 29357940
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (psychological preparation and distraction strategy)
Study: 29358961
Drug: Verum acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum acupuncture (VA) group 1 (3 times weekly for 4 weeks)
Study: 29358961
Drug: Verum acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum acupuncture (VA) group 2 (twice weekly for 4 weeks)
Study: 29358961
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture group (SA; twice weekly for 4 weeks)
Study: 29360184
Drug: Single-agent post-transplantation
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent post-transplantation cyclophosphamide (PTCy) for MBM grafts
Study: 29360184
Drug: PTCy, tacrolimus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTCy, tacrolimus, and mycophenolate mofetil (MMF) 30 mg/kg for MPBSC grafts
Study: 29360184
Drug: PTCy, tacrolimus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTCy, tacrolimus, and MMF 45 mg/kg for MMG grafts
Study: 29360184
Drug: Combination arms
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination arms (PTCy, tacrolimus, and MMF)
Study: 29360414
Drug: Radiotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy after chemotherapy
Study: 29360462
Drug: Large SPSS
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large SPSS (L-SPSS, ≥8 mm)
Study: 29360462
Drug: SPSS (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPSS (both L-SPSS and S-SPSS)
Study: 29360526
Drug: Ibrutinib therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib therapy, short-term, dosage and duration not specified
Study: 29361097
Drug: 4.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 g/day multimatrix mesalamine for 8 weeks (induction period)
Study: 29361097
Drug: 2.4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g/day multimatrix mesalamine for 12 additional months (maintenance period)